Cancer Screening Rates Rebound Post-Pandemic

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on March 6, 2025.

By Dennis Thompson HealthDay Reporter

THURSDAY, March 6, 2025 -- Preventive screenings for cancer declined during the pandemic, with lockdowns, social distancing and COVID-19 surges keeping many from needed mammograms and colonoscopies.

But breast and colon cancer screening numbers have since rebounded and have even surpassed pre-pandemic screening estimates, a new American Cancer Society study has found.

“These findings are mostly encouraging as the pandemic resulted in widespread disruptions in cancer screening in the U.S.,” lead researcher Jessica Star, an associate scientist of cancer risk factors and screening surveillance research at the American Cancer Society, said in a news release.

Unfortunately, the good news doesn’t extend to cervical cancer screenings, which remain below pre-pandemic levels, researchers reported March 5 in the Journal of the American Medical Association.

“The continued decline in cervical cancer screening is troubling as diagnoses of cervical cancers at an early stage, when they are more treatable, also decreased during the pandemic,” Star said. “Without returns to cervical cancer screening, prevention and early-stage diagnoses may continue to drop and put more lives at risk.”

For the study, researchers analyzed responses to the National Health Interview Survey, an annual poll conducted by the U.S. Centers for Disease Control and Prevention (CDC).

The team compared cancer screening rates in 2019, before the pandemic, to those in 2021 during the pandemic and in 2023 after the end of the global health crisis.

Results show that breast and colon cancer screenings in 2023 exceeded 2019 levels by 7% and 12% respectively, due to sharp increases toward the end of the pandemic.

Meanwhile, cervical cancer screening in 2023 remained 14% below 2019 levels, with no change between 2021 and 2023, researchers found.

“The persistent decline in cervical cancer screening may in part reflect longer-term declines in patient knowledge and clinicians recommending the test,” Star said. “It’s imperative that we continue to advocate for returns to cervical cancer screening and efforts must also address the widening disparities in all cancer screenings by socioeconomic status.”

In addition, the rebound in screening for breast and colon cancers occurred mainly among people who make more money, have higher education and are either privately insured or Medicare recipients, researchers found.

“Health systems and health care professionals could play a major role by improving screening communications and providing patient navigators to help address structural and cost barriers,” researchers concluded in the study.

Sources

  • American Cancer Society, news release, March 5, 2025
  • Journal of the American Medical Association, March 5, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-03-07 00:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords